Liquidia Corporation LQDA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program Expenses by Product | ||||||
| Generic Treprostinil | -$49K-173% | $67K+219% | $21K-83.2% | $125K-17.2% | $151K+21.8% | |
| L606 | $5.82M-44.1% | $10.42M+226% | $3.2M+14.5% | $2.79M-14.5% | $3.27M-54.1% | |
| Yutrepia | $15.89M+2.3% | $15.54M+0.3% | $15.49M+5.6% | $14.66M+50.2% | $9.76M-46.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Liquidia Corporation break its business down?
- Liquidia Corporation (LQDA) reports program expenses by product across 3 parts — Generic Treprostinil, L606 and Yutrepia. Each is extracted from the segment footnotes and tracked over time.
- Where does Liquidia Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Liquidia Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
